Press "Enter" to skip to content

Biocon extends licensing pact with Equillium for itolizumab

Itolizumab, a first-in-class humanized anti-CD6 monoclonal antibody, is developed by Biocon and launched in 2013 in India under the brand name ALZUMAb to treat moderate to severe plaque psoriasis, a skin disease.

Original source:

Also Read:   Pharma company accountant held for sharing its data with rival firm